• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
Introduction Gout affects 2.5% of the UK's adult population and is now the most common type of inflammatory arthritis. The long-term management of gout requires reduction of serum urate levels and this is most often achieved with use of xanthine oxidase inhibitors, such as allopurinol. Febuxostat is the first new xanthine oxidase inhibitor since allopurinol and was licensed for use in 2008. The European Medicines Agency requested a postlicensing cardiovascular safety study of febuxostat versus allopurinol, which has been named the Febuxostat versus Allopurinol Streamlined trial (FAST). Methods and analysis FAST is a cardi...
Source: BMJ Open - July 10, 2014 Category: Journals (General) Authors: MacDonald, T. M., Ford, I., Nuki, G., Mackenzie, I. S., De Caterina, R., Findlay, E., Hallas, J., Hawkey, C. J., Ralston, S., Walters, M., Webster, J., McMurray, J., Perez Ruiz, F., Jennings, C. G., MacDonald, Ford, Nuki, Mackenzie, Hallas, Webster, Walte Tags: Open access, Cardiovascular medicine, Research methods Protocol Source Type: research

Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study
Introduction Ischaemic heart disease (IHD) is one of the most common causes of death in the UK and treatment of patients with IHD costs the National Health System (NHS) billions of pounds each year. Allopurinol is a xanthine oxidase inhibitor used to prevent gout that also has several positive effects on the cardiovascular system. The ALL-HEART study aims to determine whether allopurinol improves cardiovascular outcomes in patients with IHD. Methods and analysis The ALL-HEART study is a multicentre, controlled, prospective, randomised, open-label blinded end point (PROBE) trial of allopurinol (up to 600 mg daily) ver...
Source: BMJ Open - September 7, 2016 Category: Journals (General) Authors: Mackenzie, I. S., Ford, I., Walker, A., Hawkey, C., Begg, A., Avery, A., Taggar, J., Wei, L., Struthers, A. D., MacDonald, T. M., on behalf of the ALL-HEART study group Tags: Open access, Cardiovascular medicine, Pharmacology and therapeutics Protocol Source Type: research